Literature DB >> 21093298

Attenuation of early airway obstruction by mesenchymal stem cells in a murine model of heterotopic tracheal transplantation.

Daniel A Grove1, Jianguo Xu, Robert Joodi, Edilson Torres-Gonzales, David Neujahr, Ana L Mora, Mauricio Rojas.   

Abstract

BACKGROUND: Long-term success in lung transplantation is limited by obliterative bronchiolitis (OB). Presently, complete understanding of the mechanisms of OB has been elusive. Bone marrow-derived mesenchymal stem cells (MSC) have been shown to modulate repair of the injured lung in multiple disease models. We hypothesized that the injection of MSC would prevent development of early airway obstruction (AO) in the heterotopic tracheal transplant model.
METHODS: Forty-four tracheas from BALB/c and C57BL/6 donors were transplanted into 22 C57BL/6 recipients. At the time of transplant, 13 of the allogeneic recipient mice were injected with 5 × 10(5) MSC from various murine sources. To confirm the role of the immune response in the generation of AO we used a permeable inhibitor of nuclear factor-kappaB (NF-κB) in 11 recipients after transplantation with 22 BALB/c tracheas.
RESULTS: After transplantation, administration of MSC inhibited intraluminal obstruction by collagen in 98% of the mice and transforming factor-beta (TGF-β) expression decreased to levels similar to those observed in isograft controls. These effects were associated with a significant (p < 0.05) increase in expression of the anti-inflammatory cytokine interleukin-10 (IL-10). NF-κB inhibitor showed decreased expression of transforming growth factor-beta (TGF-β) in the Day 7 and Day 14 groups, resulting in a 60% reduction of luminal obstruction as well as a decrease in inflammatory cells to the airway.
CONCLUSION: Our observations suggest that administration of MSC prevents development of airway occlusion in a mouse model, probably through the modulated immune response altering TGF-β expression.
Copyright © 2011 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21093298      PMCID: PMC3395061          DOI: 10.1016/j.healun.2010.09.012

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  18 in total

1.  Genetic engineering of proteins with cell membrane permeability.

Authors:  M Rojas; J P Donahue; Z Tan; Y Z Lin
Journal:  Nat Biotechnol       Date:  1998-04       Impact factor: 54.908

Review 2.  Marrow stromal cells as stem cells for nonhematopoietic tissues.

Authors:  D J Prockop
Journal:  Science       Date:  1997-04-04       Impact factor: 47.728

3.  'Green mice' as a source of ubiquitous green cells.

Authors:  M Okabe; M Ikawa; K Kominami; T Nakanishi; Y Nishimune
Journal:  FEBS Lett       Date:  1997-05-05       Impact factor: 4.124

4.  Radiation pneumonitis in mice: a severe injury model for pneumocyte engraftment from bone marrow.

Authors:  Neil D Theise; Octavian Henegariu; Joanna Grove; Jayishree Jagirdar; Peter N Kao; James M Crawford; Sunil Badve; Romil Saxena; Diane S Krause
Journal:  Exp Hematol       Date:  2002-11       Impact factor: 3.084

5.  Bone marrow-derived mesenchymal stem cells in repair of the injured lung.

Authors:  Mauricio Rojas; Jianguo Xu; Charles R Woods; Ana L Mora; Willy Spears; Jesse Roman; Kenneth L Brigham
Journal:  Am J Respir Cell Mol Biol       Date:  2005-05-12       Impact factor: 6.914

6.  Poly (ADP) ribose synthetase inhibition reduces obliterative airway disease in rat tracheal allografts.

Authors:  Alexander S Farivar; Steven M Woolley; Babu V Naidu; Charles H Fraga; Karen Byrne; Robert Thomas; Andrew L Salzman; Csaba S Szabo; Michael S Mulligan
Journal:  J Heart Lung Transplant       Date:  2004-08       Impact factor: 10.247

Review 7.  Mesenchymal stem cells and inflammatory lung diseases.

Authors:  S S Iyer; C Co; M Rojas
Journal:  Panminerva Med       Date:  2009-03       Impact factor: 5.197

8.  T-cell and major histocompatibility complex requirements for obliterative airway disease in heterotopically transplanted murine tracheas.

Authors:  K E Kelly; M I Hertz; D L Mueller
Journal:  Transplantation       Date:  1998-09-27       Impact factor: 4.939

9.  Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy.

Authors:  Jeffrey L Spees; Carl A Gregory; Harpreet Singh; H Alan Tucker; Alexandra Peister; Patrick J Lynch; Shu-Ching Hsu; Jason Smith; Darwin J Prockop
Journal:  Mol Ther       Date:  2004-05       Impact factor: 11.454

10.  Reproduction of the obliterative bronchiolitis lesion after heterotopic transplantation of mouse airways.

Authors:  M I Hertz; J Jessurun; M B King; S K Savik; J J Murray
Journal:  Am J Pathol       Date:  1993-06       Impact factor: 4.307

View more
  16 in total

1.  Stem cells and cell therapies in lung biology and diseases: conference report.

Authors:  Daniel J Weiss; Jason H T Bates; Thomas Gilbert; W Conrad Liles; Carolyn Lutzko; Jay Rajagopal; Darwin Prockop
Journal:  Ann Am Thorac Soc       Date:  2013-10

2.  Stem cells and cell therapies in lung biology and lung diseases.

Authors:  Daniel J Weiss; Ivan Bertoncello; Zea Borok; Carla Kim; Angela Panoskaltsis-Mortari; Susan Reynolds; Mauricio Rojas; Barry Stripp; David Warburton; Darwin J Prockop
Journal:  Proc Am Thorac Soc       Date:  2011-06

3.  Aging mesenchymal stem cells fail to protect because of impaired migration and antiinflammatory response.

Authors:  Martha L Bustos; Luai Huleihel; Maria G Kapetanaki; Christian L Lino-Cardenas; Lyle Mroz; Bryon M Ellis; Bryan J McVerry; Thomas J Richards; Naftali Kaminski; Nayra Cerdenes; Ana L Mora; Mauricio Rojas
Journal:  Am J Respir Crit Care Med       Date:  2014-04-01       Impact factor: 21.405

Review 4.  Stem cells and regenerative medicine in lung biology and diseases.

Authors:  Allison N Lau; Meagan Goodwin; Carla F Kim; Daniel J Weiss
Journal:  Mol Ther       Date:  2012-03-06       Impact factor: 11.454

5.  Mesenchymal stem cells attenuate vascular remodeling in monocrotaline-induced pulmonary hypertension rats.

Authors:  Jiang Xie; Dayi Hu; Lili Niu; Suping Qu; Shenghao Wang; Shuang Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-12-28

6.  Cardiopulmonary and histological characterization of an acute rat lung injury model demonstrating safety of mesenchymal stromal cell infusion.

Authors:  Rudolf K Braun; Jill M Koch; Timothy A Hacker; David Pegelow; Jaehyup Kim; Amish N Raval; Eric G Schmuck; Denise J Schwahn; Derek J Hei; John M Centanni; Marlowe Eldridge; Peiman Hematti
Journal:  Cytotherapy       Date:  2016-04       Impact factor: 5.414

7.  Treatment with placenta-derived mesenchymal stem cells mitigates development of bronchiolitis obliterans in a murine model.

Authors:  Yunge Zhao; Jacob R Gillen; David A Harris; Irving L Kron; Michael P Murphy; Christine L Lau
Journal:  J Thorac Cardiovasc Surg       Date:  2013-11-04       Impact factor: 5.209

8.  Parkinson's disease and mesenchymal stem cells: potential for cell-based therapy.

Authors:  Masaaki Kitada; Mari Dezawa
Journal:  Parkinsons Dis       Date:  2012-02-28

9.  XB130 deficiency affects tracheal epithelial differentiation during airway repair.

Authors:  Jinbo Zhao; Yingchun Wang; Andrew Wakeham; Zhenyue Hao; Hiroaki Toba; Xiaohui Bai; Shaf Keshavjee; Tak W Mak; Mingyao Liu
Journal:  PLoS One       Date:  2014-10-01       Impact factor: 3.240

Review 10.  Potential clinical applications of adult human mesenchymal stem cell (Prochymal®) therapy.

Authors:  Amit N Patel; Jorge Genovese
Journal:  Stem Cells Cloning       Date:  2011-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.